Loading
Mineralys Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 31 Mar 2026.
Mineralys Therapeutics, Inc.: what insiders have been doing
Mineralys Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 91 filings came from 17 insiders.
Both sides are active: 2 purchases worth €7.6M and 22 sales worth €45.5M, from 1 insider and 6 insiders respectively. The totals do not cover 2 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 senior executive. The largest single trade was a sale of €37.6M by Slingsby Brian Taylor, published on 21 November 2025.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 91 filings here. Since 2023, the database holds 13 purchases and 42 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -154.7 m USD.
The last insider purchase was made public on 31 March 2026, 201 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
157
Thresholds
n/a
Buy Volume
€80M
13 ops. · all time
Sell Volume
€57M
42 ops. · all time
Who traded when
BuySaleJon Congleton12 sales
Rodman David Malcom12 sales
Levy Adam Scott6 sales
RA Capital Management, L.P.4 buys
Brian Taylor Slingsby1 buy2 sales
Eric Warren3 sales
+3 other insiders
Since the insiders bought
- +2.2%Entry US$26.41 · Close at T+90 US$26.98
- -20.8%Entry US$38.50 · Close at T+365 US$30.50
- +99.0%Entry US$13.56 · Close at T+365 US$26.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Mineralys Therapeutics, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$46.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.23
Analyst consensus
9 analystsStrong buy
US$29.00Target US$46.33(+108%)US$56.00
Income statement
EBITDA-US$170.5M
Net income-US$154.7M0.0% margin
Valuation
PER (forward)-9.0x
P/Book3.6x
Beta0.69
Balance sheet & cash
Market capUS$2B
Free Cash Flow-US$142.4M
Debt / Equity18%
Profitability & ownership
ROE-80.9%
ROA-46.2%
% insiders0.7%
% institutions117.5%
Last declaration on 13 October 2026
Declarations157 total
3,542 shares@ US$22.040.0040% mcap1.7% of flowCommon stockSEC144:0001964306-26-000466
75,000 shares@ US$25.46220.088% mcap18.7% of flowCommon StockSEC:0001933414-26-000121:0
75,000 shares@ US$25.46220.088% mcap23.0% of flowCommon StockSEC144:0001964306-26-000459
104,320 shares@ US$28.80850.13% mcap5.2% of flowCommon StockSEC:0001963901-26-000003:0
104,320 shares@ US$28.80850.13% mcap100.0% of flowCommonSEC144:0001950047-26-009734
7,438 shares@ US$13.240.0042% mcap2.3% of flowCommon StockSEC:0001916048-26-000014:0
7,438 shares@ US$28.11720.0088% mcap5.0% of flowCommon StockSEC:0001916048-26-000014:1
7,438 shares@ US$28.11720.0088% mcap5.0% of flowCommon StockSEC144:0001964306-26-000453
417 shares@ US$27.950.0005% mcap0.2% of flowCommon stockSEC144:0001964306-26-000448
3,000 shares@ US$12.020.0015% mcap7.8% of flowCommon StockSEC:0001816952-26-000005:0
3,000 shares@ US$28.580.0036% mcap18.6% of flowCommon StockSEC144:0001964306-26-000445
7,709 shares@ US$28.140.0091% mcap4.5% of flowCommon stockSEC144:0001964306-26-000440
2,171 shares@ US$30.870.0028% mcap1.4% of flowCommon stockSEC144:0001964306-26-000434
7,437 shares@ US$13.240.0041% mcap2.3% of flowCommon StockSEC:0001916048-26-000012:0
7,437 shares@ US$25.97670.0080% mcap4.5% of flowCommon StockSEC:0001916048-26-000012:1
7,437 shares@ US$25.97670.0080% mcap4.5% of flowCommon StockSEC144:0001964306-26-000406
417 shares@ US$25.460.0004% mcap0.2% of flowCommon stockSEC144:0001964306-26-000390
14,056 shares@ US$26.47890.016% mcap7.8% of flowCommon stockSEC144:0001964306-26-000385
102,400 shares0Common StockSEC:0001933414-26-000120:0
2,170 shares@ US$16.000.0015% mcap0.7% of flowCommon StockSEC:0001933414-26-000118:0
2,170 shares@ US$27.090.0025% mcap1.2% of flowCommon stockSEC144:0001964306-26-000377
7,438 shares@ US$13.240.0042% mcap2.3% of flowCommon StockSEC:0001916048-26-000009:0
7,438 shares@ US$26.87350.0085% mcap4.8% of flowCommon StockSEC:0001916048-26-000009:1
7,438 shares@ US$26.87350.0085% mcap4.8% of flowCommon StockSEC144:0001964306-26-000324
416 shares@ US$15.440.0003% mcap0.1% of flowCommon StockSEC:0001672659-26-000036:0
25 of 157 declarations
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (ticker: MLYS) is a U.S.-based biopharmaceutical company listed on the Nasdaq in the United States. The company is focused on cardiometabolic and cardiorenal disease, with a development strategy centered on hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA). From an equity-research perspective, Mineralys fits the profile of a clinical-stage biotech: it has no commercial product revenue yet, and its valuation is primarily driven by clinical execution, regulatory milestones, financing capacity, and the probability of future commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001933414/000193341426000056/mlys-20251231.htm?utm_source=openai))
Mineralys was incorporated in Delaware in May 2019 and is headquartered in Radnor, Pennsylvania. Its corporate history includes an earlier name, Catalys SC1, Inc., before the company was renamed Mineralys Therapeutics, Inc. The business has followed the classic biotech path of building a pipeline, advancing clinical assets, and funding operations through public markets and other capital raises. The company completed its IPO in February 2023, which helped finance research, clinical trials, and broader development activities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1933414/000193341424000057/R9.htm?utm_source=openai))
Read moreShow less
The company’s lead asset is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor. Mineralys is developing lorundrostat for diseases associated with dysregulated aldosterone, primarily hypertension, but also CKD and OSA. Recent SEC filings indicate that Mineralys has completed two pivotal trials in hypertension and Phase 2 studies in CKD and OSA, which places the program in the advanced clinical-development category. That is an important distinction for investors: the asset is no longer purely preclinical, but it still carries meaningful development and approval risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001933414/000193341426000056/mlys-20251231.htm?utm_source=openai))
In competitive terms, Mineralys is attempting to differentiate itself in a large and crowded hypertension market by targeting aldosterone biology more directly. The rationale is that a more selective mechanism could improve blood-pressure control and potentially address overlapping renal and sleep-apnea comorbidities. For investors, that creates a potentially attractive precision-mechanism thesis, but it also means the stock remains highly sensitive to clinical data readouts, regulatory decisions, and capital-market conditions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001933414/000193341426000056/mlys-20251231.htm?utm_source=openai))
Among the most important recent developments, Mineralys disclosed that it submitted an NDA to the FDA in December 2025 for lorundrostat in hypertension, with a PDUFA target action date of December 22, 2026. The company also completed an upsized public offering in September 2025, raising approximately $287.5 million in gross proceeds to support clinical development, manufacturing, pre-commercial activities, and general corporate purposes. Taken together, these events suggest the company is moving from late-stage clinical execution toward potential commercialization, while still operating with the financing and regulatory profile typical of a development-stage biotech. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001933414/000193341426000056/mlys-20251231.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
